Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)

NCT05285904 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05285904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05285904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
May 12, 2022
Completion date
February 4, 2026
Enrollment
107 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis